The PI3K Inhibitor XH30 Enhances Response to Temozolomide in Drug-Resistant Glioblastoma via the Noncanonical Hedgehog Signaling Pathway
Glioblastoma multiforme (GBM) is the most common malignant tumor of the central nervous system. Temozolomide (TMZ)–based adjuvant treatment has improved overall survival, but clinical outcomes remain poor; TMZ resistance is one of the main reasons for this. Here, we report a new phosphatidylinositid...
Guardado en:
Autores principales: | Ming Ji, Zhihui Zhang, Songwen Lin, Chunyang Wang, Jing Jin, Nina Xue, Heng Xu, Xiaoguang Chen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/59f6de3fccf24808aa6aaf913c3d6154 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Identification of Differentially Expressed Genes in Different Glioblastoma Regions and Their Association with Cancer Stem Cell Development and Temozolomide Response
por: Justin Bo-Kai Hsu, et al.
Publicado: (2021) -
Interplay of m6A and histone modifications contributes to temozolomide resistance in glioblastoma
por: Fuxi Li, et al.
Publicado: (2021) -
Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells
por: Luca X. Zampieri, et al.
Publicado: (2021) -
Role of Hedgehog–Gli1 signaling in the enhanced proliferation and differentiation of MG63 cells enabled by hierarchical micro-/nanotextured topography
por: Lin Y, et al.
Publicado: (2017) -
Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH2 Through Ultrasound to Enhance the Antitumor Efficacy and Attenuate the Toxicity for Treatment of Malignant Glioma
por: Wan Z, et al.
Publicado: (2021)